(2026). Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLOS ONE.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Correction: Economic Evaluation of Atezolizumab in Combination with Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer in China: A Cost-effectiveness Analysis."
PLOS ONE 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Correction: Economic Evaluation of Atezolizumab in Combination with Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer in China: A Cost-effectiveness Analysis."
PLOS ONE, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.